These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1049 related articles for article (PubMed ID: 15780499)

  • 1. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
    Menendez JA; Ropero S; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Jun; 24(6):1369-83. PubMed ID: 15138577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene.
    Menendez JA; Vellon L; Oza BP; Lupu R
    J Cell Biochem; 2005 Apr; 94(5):857-63. PubMed ID: 15669079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
    Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
    Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere).
    Menendez JA; Lupu R; Colomer R
    Breast Cancer Res Treat; 2004 Mar; 84(2):183-95. PubMed ID: 14999148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis.
    Menendez JA; Colomer R; Lupu R
    Med Hypotheses; 2005; 64(2):337-41. PubMed ID: 15607568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?
    Menendez JA; Colomer R; Lupu R
    Med Hypotheses; 2005; 64(2):342-9. PubMed ID: 15607569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into anti-HER-2 receptor monoclonal antibody research.
    Kumar R; Mandal M; Vadlamudi R
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    Menendez JA; Mehmi I; Lupu R
    J Clin Oncol; 2006 Aug; 24(23):3735-46. PubMed ID: 16847284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.
    Damiano V; Garofalo S; Rosa R; Bianco R; Caputo R; Gelardi T; Merola G; Racioppi L; Garbi C; Kandimalla ER; Agrawal S; Tortora G
    Clin Cancer Res; 2009 Nov; 15(22):6921-30. PubMed ID: 19903791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.